Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. In this study, we evaluated whether a precise blood test could perform as well as established cerebrospinal fluid (CSF) tests in detecting amyloid-β (Aβ) plaques and tau tangles. Plasma %p-tau217 (ratio of phosporylated-tau217 to non-phosphorylated tau) was analyzed by mass spectrometry in the Swedish BioFINDER-2 cohort (n = 1,422) and the US Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight ADRC) cohort (n = 337). Matched CSF samples were analyzed with clinically used and FDA-approved automated immunoassays for Aβ42/40 and…

• AA
  Alzheimer's Association

  Awards: ZEN24-1069572, SG-23-1061717
• CA
  Cure Alzheimer's Fund
• AG
  Australian Government
• GF
  GHR Foundation

  Award: 2022-00775
• AR
  Alzheimer's Research Trust
• EC
  European Commission

  Awards: 101096455, 101061836
• LU
  Lunds Universitet
• KO
  Knut och Alice Wallenbergs Stiftelse

  Award: 2022-0231
• V
  Vetenskapsrådet

  Awards: 2022-00775, FO2021-0293, AF-980907, 1412/22
• KG
  Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse

  Award: 2020-O000028
• A
  Alzheimerfonden

  Award: AF-980907
• SU
  Skånes universitetssjukhus

  Awards: 2022-1259, 2020-O000028, 2022-Projekt0080
• P
  Parkinsonfonden

  Award: 1412/22
• CF
  Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis
• NI
  National Institute on Aging

  Award: R01AG083740